Sex-specific prolactin disturbance and divergent gonadal hormone correlates in first-episode schizophrenia

Anle Pan, Jindong Wang, Jing Liang, Meihong Xiu, Qiang Hu, Shuangli ZhangThe International Journal of Neuropsychopharmacology 2025 · DOI

TL;DR

This study reveals that males with first-episode schizophrenia are significantly more likely to have abnormal prolactin (PRL) levels than females. Furthermore, the relationships between PRL and other sex hormones differ markedly between sexes and across PRL levels, suggesting a sex-specific neuroendocrine signature at the onset of psychosis that warrants tailored monitoring and intervention.

What Problem Does This Paper Address?

Schizophrenia is a complex disorder with a significant impact on individuals worldwide. While disruptions in the pituitary-hypothalamus-adrenal (HPA) axis and related hormones, including prolactin (PRL), are known to be associated with schizophrenia, much of the research has treated patients as a homogenous group. Specifically, the paper highlights a gap in understanding how PRL disturbances and their interplay with gonadal hormones might differ between males and females, particularly in the early stages of the illness (first-episode schizophrenia, FES) before significant medication effects can confound results. This is crucial because gonadal hormones play vital roles in brain development and function, and their dysregulation could contribute to the pathophysiology of schizophrenia. Previous studies have hinted at sex-specific endocrine differences, but a clear picture of sex-specific PRL dysregulation and its gonadal hormone correlates at illness onset was lacking.

Methods

The researchers conducted a cross-sectional study involving 189 patients diagnosed with first-episode schizophrenia (FES) who were either antipsychotic-naïve or had received treatment for no more than two weeks. This "minimally treated" approach was key to minimizing medication-induced endocrine changes.

The core methodology involved:

  • Blood Sample Collection: Fasting venous blood samples were collected from all participants in the early morning (07:30 AM) after an overnight fast.
  • Hormone Measurement: Serum levels of prolactin (PRL), estradiol (E2), follicle-stimulating hormone (FSH), progesterone (P), luteinizing hormone (LH), and testosterone (T) were quantified using chemiluminescence immunoassays on a Beckman UniCel DxI800A analyzer. The laboratory adhered to strict quality control measures to ensure accuracy.
  • Statistical Analysis: Data were analyzed using SPSS. Chi-square tests were used for categorical variables, while Shapiro-Wilk tests and Q-Q plots assessed normality for continuous variables. ANOVA was used for normally distributed data, and the Mann-Whitney U test for non-normally distributed data. Spearman's rank correlation analysis was employed to examine associations between PRL and gonadal hormones, accounting for non-normal distributions. Bonferroni correction was applied to mitigate the risk of Type I errors in multiple comparisons.

Datasets

The study utilized data collected from 189 first-episode schizophrenia patients recruited from three public hospitals in China. No new datasets or benchmarks were introduced; the study relied on existing patient data.

Key Insights and Ideas

  • Sex Differences in PRL Abnormalities: The most striking finding is the significantly higher prevalence of abnormal PRL levels in males (32.3%) compared to females (8.6%) in this FES cohort. This suggests a sex-specific vulnerability to PRL dysregulation at the onset of schizophrenia.
  • Divergent Gonadal Hormone Correlates: The study uncovered distinct relationships between PRL and gonadal hormones depending on whether PRL levels were abnormal or normal, and importantly, these relationships differed between sexes (though the paper primarily focuses on the abnormal vs. normal PRL groups, the implications are sex-specific).
  • In the elevated PRL group, PRL positively correlated with progesterone and testosterone.
  • In the normal PRL group, PRL showed positive associations with estradiol and luteinizing hormone, but a negative correlation with progesterone.
  • Implications for Pathophysiology: These sex-divergent neuroendocrine signatures at psychosis onset suggest that PRL dysregulation is not a uniform phenomenon in schizophrenia. Understanding these sex-specific patterns could be crucial for developing more targeted and effective early interventions.

Key Results

  • PRL Abnormalities: Abnormal PRL levels were found in 32.3% of males and 8.6% of females, a statistically significant difference (χ² = 16.2, P < .001).
  • Hormone Levels in Elevated PRL Group: Patients with elevated PRL levels (n=39) showed significantly higher levels of follicle-stimulating hormone (FSH) (Z = 2.7, P = .007) and testosterone (T) (Z = 3.7, P < .001) compared to those with normal PRL levels (n=150).
  • Correlations in Elevated PRL Group: In the elevated PRL group, PRL positively correlated with progesterone (r=0.38, P=.02) and testosterone (r=0.44, P=.005). After Bonferroni correction, the PRL-testosterone association remained significant.
  • Correlations in Normal PRL Group: In the normal PRL group, PRL positively correlated with estradiol (E2) (r=0.33, P < .001) and luteinizing hormone (LH) (r=0.32, P < .001), and negatively correlated with progesterone (r=-0.25, P=.002). These associations remained significant after Bonferroni correction.

Limitations and Future Work

The authors acknowledge several limitations:

  • Unmeasured Confounders: Physical activity, diet, and psychosocial stress, which can influence PRL and gonadal hormone levels, were not systematically measured or adjusted for. This is particularly relevant given the potential role of stress-induced PRL elevation in FES.
  • Menstrual Cycle Stratification: For female participants, PRL and sex hormone levels were not stratified by menstrual cycle phase, which can introduce variability and potentially bias observed correlations.
  • Antipsychotic Exposure: The inclusion of patients with up to two weeks of antipsychotic exposure could introduce confounding, as even short-term use might alter hormone levels. A strictly drug-naïve criterion would enhance internal validity.

Future research directions suggested include:

  • Longitudinal Studies: Conducting longitudinal studies to track hormone changes over time and establish causal relationships.
  • Integrating Modalities: Incorporating neuroimaging, genetic profiling, and dynamic stress assessments to gain a more comprehensive understanding of the neuroendocrine mechanisms.
  • Personalized Interventions: Using these insights to inform personalized therapeutic strategies that target PRL-gonadal hormone pathways, with a focus on sex-specific approaches.

Summary updated

Abstract

Our findings underscore the complex and sex-specific nature of PRL dysregulation and its association with gonadal hormones in FES patients. Significance Statement This work analyses the sex-specific pattern of prolactin (PRL) disturbance in antipsychotic-naïve or minimally treated first-episode schizophrenia (FES), the earliest clinical manifestation of the disorder. While hyperprolactinemia is well documented, its sex-stratified links to gonadal hormones at illness onset remain unclear. We therefore reassessed PRL and gonadal hormone levels in 189 drug-naïve or minimally treated FES patients. Results showed that abnormal PRL levels were almost four times more common in males than in females. Hyperprolactinemic patients displayed elevated testosterone and follicle-stimulating hormone, whereas normal-PRL patients exhibited inverse PRL-progesterone relationships. These findings reveal a sex-divergent neuroendocrine signature at psychosis onset, underscoring the need for sex-specific endocrine monitoring and personalized early intervention strategies that target PRL-gonadal hormone pathways.
BibTeX
@article{pan2025sex,
  author = {Anle Pan and Jindong Wang and Jing Liang and Meihong Xiu and Qiang Hu and Shuangli Zhang},
  title = {{Sex-specific prolactin disturbance and divergent gonadal hormone correlates in first-episode schizophrenia}},
  journal = {The International Journal of Neuropsychopharmacology},
  year = {2025},
  doi = {10.1093/ijnp/pyaf068},
}
Figure